Streetbeat News

HOPHF

Hemogenyx Pharmaceuticals Plc

http://silverfalconplc.com/

Industry

Research and Development in Biotechnology

Open

0.04

Mkt cap

3.1T

Volume

25K

High

1.24

P/E Ratio

-0.48

52-wk high

16.00

Low

0.04

Div yield

N/A

52-wk low

0.04

Hemogenyx Pharmaceuticals has announced a breakthrough in delivering Chimeric Bait Receptors to immune cells, enhancing the efficacy of macrophages and monocytes. This development is a significant step in their pipeline.

Portfolio Pulse from

December 06, 2024 | 7:30 am

Hemogenyx Pharmaceuticals has received IRB approval to start a Phase I clinical trial for its lead therapy, HEMO-CAR-T, targeting relapsed/refractory acute myeloid leukemia.

Portfolio Pulse from

November 22, 2024 | 8:00 am

Hemogenyx Pharmaceuticals has secured £600,000 in funding from an institutional investor to support phase I clinical trials of its HEMO-CAR-T therapy.

Portfolio Pulse from

November 11, 2024 | 8:30 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.